Danish iron metabolism specialist Pharmacosmos has announced the acquisition of AbFero Pharmaceuticals, a privately-held US pharma company dedicated to treating diseases of iron overload.
Pharmacosmos, through a US subsidiary, will acquire all assets of AbFero under a share purchase agreement for a total consideration of up to $225 million when combining upfront payments, regulatory and commercial milestones, and royalties.
"The role of iron in disease has been vastly underappreciated"The deal will see Pharmacosmos acquire all rights for AbFero’s SP-420 to advance iron chelation therapies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze